- Denali Therapeutics is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases and lysosomal storage disorders, utilizing its proprietary TransportVehicle™ platform to enhance drug delivery across the blood-brain barrier.
- In 2025, Denali made significant strides by preparing for the commercial launch of Tividenofusp alfa (DNL310) for Hunter syndrome, with a PDUFA target action date set for April 5, 2026, and initiating Phase 1 studies for DNL628 in Alzheimer's disease and DNL952 for late-onset Pompe disease.
- The company is actively collaborating with various stakeholders in the biotechnology and pharmaceutical sectors to advance its clinical pipeline, including presenting preliminary data for DNL126 at the 2026 WORLDSymposium™ to support accelerated approval in Sanfilippo syndrome type A.
- Denali's ideal buyers are pharmaceutical companies and healthcare providers looking for cutting-edge treatments for complex neurodegenerative conditions, addressing critical unmet needs in patient care and offering potential for significant market impact as they prepare for upcoming product launches.
Engineering is the largest function with 172 employees (about 42% of the workforce), indicating a substantial emphasis on building and scaling core platforms and capabilities. Business Management (54) and Healthcare (43) are the next largest groups, followed by Operations (36) and Finance and Administration (24). Additional functions include Sales and Support (14), Information Technology (12), Human Resources (12), and Quality (10), with 37 employees categorized as Other. The mix shows a technology- and science-heavy organization supported by key business and operations teams.
Headcount is concentrated in the Bay Area, led by San Francisco with 183 employees (about 44%) and South San Francisco with 63 (about 15%). Additional presence spans Salt Lake City (13), San Mateo (9), Fremont (7), Oakland (6), San Jose (6), Boston (5), and Chicago (5), with 117 employees grouped under Other locations. In total, the company’s footprint covers 24 locations, with roughly two-thirds of employees based in or around the San Francisco Bay Area.
